Clinical trialPhase 1 / Phase 2Recruiting
BMS-986504 in Combination With Pemetrexed for the Treatment of Metastatic Solid Tumors With MTAP Deletion
A Phase Ib/II Basket Study of BMS-986504 in Combination With Pemetrexed for Metastatic Solid Tumors With MTAP Deletion
- Outcome
- Ongoing
- Phase
- Phase 1 / Phase 2
- Status
- Recruiting
- Study type
- Interventional
- Start
- 21 August 2026
- Expected end
- 9 December 2030
- Enrollment
- 72 participants
- Sites
- 1
- Primary outcomes
- Dose limiting toxicity; Incidence of treatment-emergent adverse events (AEs); Incidence of serious AEs; Incidence of grade 3 or greater adverse events; Number of patients who discontinue treatment due to toxicity
- Sponsor
- Other
- Results posted
- No
- Last update
- 25 August 2026
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess. Only its metadata is loaded so far, so most questions will be declined.
Try